J. Thomas Grayston Secondary Prevention Antibiotic Treatment Trials for Coronary Artery Disease
نویسنده
چکیده
Secondary Prevention Antibiotic Treatment Trials for Coronary Artery Disease Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 2000 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Circulation doi: 10.1161/01.CIR.102.15.1742 2000;102:1742-1743 Circulation. http://circ.ahajournals.org/content/102/15/1742 World Wide Web at: The online version of this article, along with updated information and services, is located on the
منابع مشابه
Antibiotic treatment trials for secondary prevention of coronary artery disease events.
The TWAR organism was described as a cause of respiratory infection in 1986.1 In 1989, it was declared a new species of Chlamydia and named Chlamydia pneumoniae.2 In 1988, Saikku et al3 reported a small seroepidemiological study suggesting a possible association between TWAR infection and atherosclerosis. Information on the association of C pneumoniae and atherosclerosis has accumulated rapidly...
متن کاملSecondary prevention antibiotic treatment trials for coronary artery disease.
Considerable interest was generated in the possible causative role of Chlamydia pneumoniae in coronary artery disease (CAD) by the publication of a small pilot study in London of antibiotic treatment of CAD that reduced coronary events.1 Persons familiar with antibiotic treatment of chlamydia were skeptical that the brief treatment schedule in the London trial (azithromycin either one or two co...
متن کاملPersistent C. pneumoniae infection in atherosclerotic lesions: rethinking the clinical trials
The hypothesis that infectious agents are a risk factor for atherosclerosis has implicated multiple viral and bacterial pathogens in contributing either directly or indirectly to disease progression (Rosenfeld and Campbell, 2011). One of the most vigorously studied organisms has been Chlamydia pneumoniae, which has been associated with cardiovascular disease by seroepidemiological studies, dete...
متن کاملAntibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events.
Since the publication of two preliminary antibiotic treatment trials for secondary prevention of cardiovascular events in persons with coronary artery disease (CAD), there has been increased interest in the possibility that the association between Chlamydia pneumoniae and atherosclerosis is causal and that antibiotic treatment can have a favorable effect on the complications and outcome of the ...
متن کاملAntibiotic treatment of atherosclerotic cardiovascular disease.
It is just 17 years since Chlamydia pneumoniae was first described and 14 years since the first observational evidence of a possible association of the organism with coronary heart disease (CHD). For 5 years there was little interest in this association, but it has subsequently attracted an increasing number of investigators. The question of an association was settled by the frequent demonstrat...
متن کامل